Statement: In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991.
Primary_evidence: Outcome Measurement:    Number of Participants With Dose Limiting Toxicities (DLT): Part 1 Phase 1   DLT was classified as per common terminology criteria for adverse events (CTCAE) version 4.0 as any of the events occurring during 28 days of Cycle 1,attributed to study drug:grade 4 neutropenia(for a duration of greater than [>]7 days); febrile neutropenia (grade greater than or equal to [>=]3 neutropenia,body temperature >=38.5 degree Celsius);grade >=3 thrombocytopenia with bleeding episode;grade 4 thrombocytopenia;grade >=3 non-hematologic toxicity except grade 3 or more nausea, vomiting,electrolyte abnormality(if controllable by therapy);grade 3 QTc prolongation(>500 millisecond [msec])persist after correction of reversible cause such as electrolyte abnormalities or hypoxia. Lack of hematologic recovery (platelets less than [<]50,000/microliter [mcL],absolute neutrophil count <1,000/mcL,hemoglobin <8.0 gram/deciliter [g/dL]) or prolonged non hematologic toxicities that delays initiation of next dose by >7 days;receipt of <75 percent of planned dose in first cycle due to toxicity.   Time frame: Lead-in period (Day -7) up to Day 28 (Cycle 1) Results 1:    Arm/Group Title: PD-0332991 100 mg: Dose Escalation Cohort   Arm/Group Description: In Phase 1-Part 1, participants received single oral dose of PD-0332991 100 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg capsule orally once daily continuously for 21 days followed by 7 days off treatment in each cycle of 28 days, unless participants experienced disease progression or unacceptable toxicity or withdrew consent.   Overall Number of Participants Analyzed: 6   Measure Type: Count of Participants   Unit of Measure: Participants  1  16.7% Results 2:    Arm/Group Title: PD-0332991 125 mg: Dose Escalation Cohort   Arm/Group Description: In Phase 1-Part 1, participants received single oral dose of PD-0332991 125 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 125 mg capsule orally once daily continuously for 21 days followed by 7 days off treatment in each cycle of 28 days, unless participants experienced disease progression or unacceptable toxicity or withdrew consent.   Overall Number of Participants Analyzed: 6   Measure Type: Count of Participants   Unit of Measure: Participants  1  16.7%